24u
Huidig
Min
217.51
Max
217.99
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | -10.28% downside |
By Acuity
53%
47%
284 / 374 Rangschikking in Healthcare
By Trading Central
Vertrouwen
Bearish Evidence
18.88 / 19.67 Steun & Weerstand
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
14 nov 2025, 12:31 UTC
Merck to Buy Cidara Therapeutics in $9.2 Billion Deal -- Update
DJ
Lezen
14 nov 2025, 12:16 UTC
Merck to Buy Cidara Therapeutics in $9.2 Billion Deal
DJ
Lezen
14 nov 2025, 11:20 UTC
Cidara Shares Nearly Double Premarket on Report of Takeover by Merck
DJ
Lezen
14 nov 2025, 11:11 UTC
Merck Nears $9.2 Billion Deal for Cidara, FT Reports, Citing Sources
DJ
Lezen
23 jun 2025, 12:05 UTC
Cidara Shares Soar Premarket After Positive Influenza Trial Results
DJ
Lezen
14 nov 2025, 16:30 UTC
Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com
DJ
Lezen
14 nov 2025, 13:19 UTC
This Biotech Stock Is Soaring 100%. Merck Is Buying It. -- Barrons.com
DJ
Lezen
14 nov 2025, 12:22 UTC
Pharma Sector Becoming Bidding Battlefield -- Market Talk
DJ
Lezen
Prijswijziging
By TipRanks
12 Maanden Prognose
Gemiddelde 195.33Ā USDĀ -10.28%
Hoogste 221.5Ā USD
Laagste 167Ā USD
Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor CIDARA THERAPEUTICS INC - Dist. in de afgelopen 3 maanden.
By TipRanks
Buy
8 ratings
4
Buy
4
Hold
0
Sell
Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan CIDARA THERAPEUTICS INC - Dist in de afgelopen 3 maanden.
By Trading Central
Korte Termijn
Bearish Evidence
Recent bearish events outweigh bullish events.
Gemiddeld Termijn
Strong Bearish Evidence
All events are bearish.
Lange Termijn
Strong Bullish Evidence
All events are bullish.
By Acuity
Nieuwssentiment
Bullish Bewijs
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Boven gemiddelde
$